Opinion/decision on a Paediatric investigation plan (PIP): Aubagio, Teriflunomide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0165/2017

Opinion/decision on a Paediatric investigation plan (PIP): Vimizim, Recombinant human N-acetylgalactosamine-6-sulfatase (elosulfase alfa), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0170/2023

EMEA-000637-PIP02-10-M07

Opinion/decision on a Paediatric investigation plan (PIP): Edurant, Rilpivirine (hydrochloride), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0101/2022

Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0541/2022

Opinion/decision on a Paediatric investigation plan (PIP): Cresemba, Isavuconazonium sulfate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0479/2021

Opinion/decision on a Paediatric investigation plan (PIP): Holoclar, Ex vivo expanded autologous human corneal epithelium cells containing stem cells, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Ophthalmology, PIP number: P/0066/2022

Opinion/decision on a Paediatric investigation plan (PIP): Onglyza, Saxagliptin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0478/2022

Opinion/decision on a Paediatric investigation plan (PIP): Hepcludex, Bulevirtide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0270/2022

Opinion/decision on a Paediatric investigation plan (PIP): Cystadrops, Cysteamine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Ophthalmology, PIP number: P/0019/2022